BMY
Price
$57.66
Change
+$1.79 (+3.20%)
Updated
Dec 17, 04:59 PM (EDT)
50 days until earnings call
GILD
Price
$92.79
Change
+$0.74 (+0.80%)
Updated
Dec 17, 04:59 PM (EDT)
55 days until earnings call
Ad is loading...

BMY vs GILD

Header iconBMY vs GILD Comparison
Open Charts BMY vs GILDBanner chart's image
Bristol-Myers Squibb
Price$57.66
Change+$1.79 (+3.20%)
Volume$66.67K
CapitalizationN/A
Gilead Sciences
Price$92.79
Change+$0.74 (+0.80%)
Volume$102.55K
CapitalizationN/A
BMY vs GILD Comparison Chart
Loading...
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BMY vs. GILD commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BMY is a Hold and GILD is a Buy.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (BMY: $57.65 vs. GILD: $92.80)
Brand notoriety: BMY and GILD are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: BMY: 142% vs. GILD: 94%
Market capitalization -- BMY: $109.66B vs. GILD: $90.79B
BMY [@Pharmaceuticals: Major] is valued at $109.66B. GILD’s [@Pharmaceuticals: Major] market capitalization is $90.79B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BMY’s FA Score shows that 1 FA rating(s) are green whileGILD’s FA Score has 3 green FA rating(s).

  • BMY’s FA Score: 1 green, 4 red.
  • GILD’s FA Score: 3 green, 2 red.
According to our system of comparison, GILD is a better buy in the long-term than BMY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BMY’s TA Score shows that 4 TA indicator(s) are bullish while GILD’s TA Score has 3 bullish TA indicator(s).

  • BMY’s TA Score: 4 bullish, 4 bearish.
  • GILD’s TA Score: 3 bullish, 4 bearish.
According to our system of comparison, BMY is a better buy in the short-term than GILD.

Price Growth

BMY (@Pharmaceuticals: Major) experienced а -0.81% price change this week, while GILD (@Pharmaceuticals: Major) price change was +1.34% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.90%. For the same industry, the average monthly price growth was -3.44%, and the average quarterly price growth was -1.16%.

Reported Earning Dates

BMY is expected to report earnings on Feb 06, 2025.

GILD is expected to report earnings on Feb 11, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (-1.90% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BMY($110B) has a higher market cap than GILD($90.8B). GILD has higher P/E ratio than BMY: GILD (16.20) vs BMY (13.73). GILD YTD gains are higher at: 19.235 vs. BMY (18.037). BMY has higher annual earnings (EBITDA): 19.4B vs. GILD (10.5B). BMY has more cash in the bank: 12.3B vs. GILD (7.26B). GILD has less debt than BMY: GILD (25B) vs BMY (41.5B). BMY has higher revenues than GILD: BMY (45B) vs GILD (27.1B).
BMYGILDBMY / GILD
Capitalization110B90.8B121%
EBITDA19.4B10.5B185%
Gain YTD18.03719.23594%
P/E Ratio13.7316.2085%
Revenue45B27.1B166%
Total Cash12.3B7.26B169%
Total Debt41.5B25B166%
FUNDAMENTALS RATINGS
BMY vs GILD: Fundamental Ratings
BMY
GILD
OUTLOOK RATING
1..100
6522
VALUATION
overvalued / fair valued / undervalued
1..100
9
Undervalued
90
Overvalued
PROFIT vs RISK RATING
1..100
6916
SMR RATING
1..100
9688
PRICE GROWTH RATING
1..100
4415
P/E GROWTH RATING
1..100
941
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BMY's Valuation (9) in the Pharmaceuticals Major industry is significantly better than the same rating for GILD (90) in the Biotechnology industry. This means that BMY’s stock grew significantly faster than GILD’s over the last 12 months.

GILD's Profit vs Risk Rating (16) in the Biotechnology industry is somewhat better than the same rating for BMY (69) in the Pharmaceuticals Major industry. This means that GILD’s stock grew somewhat faster than BMY’s over the last 12 months.

GILD's SMR Rating (88) in the Biotechnology industry is in the same range as BMY (96) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to BMY’s over the last 12 months.

GILD's Price Growth Rating (15) in the Biotechnology industry is in the same range as BMY (44) in the Pharmaceuticals Major industry. This means that GILD’s stock grew similarly to BMY’s over the last 12 months.

GILD's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for BMY (94) in the Pharmaceuticals Major industry. This means that GILD’s stock grew significantly faster than BMY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BMYGILD
RSI
ODDS (%)
Bearish Trend 6 days ago
50%
Bearish Trend 6 days ago
55%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
60%
Bearish Trend 1 day ago
52%
Momentum
ODDS (%)
Bearish Trend 1 day ago
57%
Bullish Trend 1 day ago
57%
MACD
ODDS (%)
Bearish Trend 1 day ago
42%
Bearish Trend 1 day ago
40%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
53%
Bullish Trend 1 day ago
57%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
54%
Bullish Trend 1 day ago
61%
Advances
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 1 day ago
60%
Declines
ODDS (%)
Bearish Trend 6 days ago
55%
Bearish Trend 10 days ago
50%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
70%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
43%
Bullish Trend 1 day ago
44%
View a ticker or compare two or three
Ad is loading...
BMY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GILD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
LICN0.180.01
+4.80%
Lichen China Limited
VNDA4.730.10
+2.16%
Vanda Pharmaceuticals
VEEV226.411.72
+0.77%
Veeva Systems
HUN18.56-0.25
-1.33%
Huntsman Corp
FWRG19.54-0.29
-1.46%
First Watch Restaurant Group

BMY and

Correlation & Price change

A.I.dvisor indicates that over the last year, BMY has been loosely correlated with JNJ. These tickers have moved in lockstep 39% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then JNJ could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BMY
1D Price
Change %
BMY100%
+3.19%
JNJ - BMY
39%
Loosely correlated
+1.78%
PFE - BMY
39%
Loosely correlated
+4.67%
ABBV - BMY
34%
Loosely correlated
+2.18%
GILD - BMY
32%
Poorly correlated
+0.81%
RHHBY - BMY
30%
Poorly correlated
+0.84%
More

GILD and

Correlation & Price change

A.I.dvisor indicates that over the last year, GILD has been loosely correlated with BIIB. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if GILD jumps, then BIIB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GILD
1D Price
Change %
GILD100%
+0.81%
BIIB - GILD
35%
Loosely correlated
+0.10%
JNJ - GILD
34%
Loosely correlated
+1.78%
BMY - GILD
32%
Poorly correlated
+3.19%
PFE - GILD
26%
Poorly correlated
+4.67%
AMGN - GILD
25%
Poorly correlated
-0.21%
More